Scientific Publications

Manuscripts are expected for all ORP approved studies. Additionally, submission of abstracts (prior to manuscript publication) for presentation are encouraged.  Please access the published manuscripts and abstracts in each disease state by clicking the links below:

Bibliography: NCCN Oncology Research Program Manuscripts

Bibliography: NCCN Oncology Research Program Abstracts

NCCN ORP Manuscripts

Angiosarcoma

Thiebaud J, Ravi V, Litwin S, Schuetze S, Movva S, Agulnik M, Kraft A, Tezlaff E, Somaiah N, von Mehren M.  A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.  Cancer . 2022 Oct 1;128(19):3516-3522. doi: 10.1002/cncr.34403. Epub 2022 Aug 9 
https://pubmed.ncbi.nlm.nih.gov/35942596/

Brain Cancer

Ly K, Richardson L, Liu M, Muzikansky A, Cardona J, Lou K, Beers A, Chang K, Brown J, Ma X, Reardon D, Arrillaga-Romany I, Forst D, Jordan J, Lee E, Dietrich J, Nayak L, Wen P, Chukwueke U, Giobbie-Hurder A, Choi B, Batchelor T, Kalpathy-Cramer J, Curry W, Gerstner E. Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2023 Aug 15;29(16):3017-3025. doi: 10.1158/1078-0432.CCR-23-0203.
https://pubmed.ncbi.nlm.nih.gov/37327319/

Breast Cancer

Marcho LM, Coss CC, Xu M, Datta J, Manouchehri JM, Cherian MA. Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells. Front Oncol. 2025 Mar 26;15:1441896. doi: 10.3389/fonc.2025.1441896. PMID: 40206590; PMCID: PMC11979155.
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1441896/full

Datta J, Willingham N, Manouchehri JM, Schnell P, Sheth M, David JJ, Kassem M, Wilson TA, Radomska HS, Coss CC, Lustberg M, Ramaswany B, Stover DG, Cherian MA. Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer. Front. Oncol., 25 April 2022 
https://doi.org/10.3389/fonc.2022.857590

Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo Lei, Damodaran S, Sun R, Moulder SL.  A Phase II Study of Mirvetuximab Soravtansine in Triple-Negative Breast Cancer.  Invest New Drugs 2021 Apr;39(2):509-515. doi: 10.1007/s10637-020-00995-2. Epub 2020 Sep 28.
https://pubmed.ncbi.nlm.nih.gov/32984932/

Gastrointestinal Cancer

Mukherjee S, Fujiwara Y, Fountzilas C, Pattnaik H, Chatley S, Vadehra D, Kukar M, Attwood K, George A, Advani S, Yu H, Catalfamo K, Brown A, Spickard E, Fungtammasan A,  George S, Liao C-Y, Iyer R, Hatoum H.  Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study.  Cancer Medicine, Volume 14, No. 7, April 2025.
https://doi.org/10.1002/cam4.70835

Boland PM, Ebos JM, Attwood K, Mastri M, Fountzilas C, Iyer RV, Banker C, Goey AKL, Bies R, Ma WW, Fakih M. A phase I/II study of nintedanib and capecitabine for refractory metastatic colorectal cancer. JNCI Cancer Spectr. 2024 Apr 30;8(3):pkae017. doi: 10.1093/jncics/pkae017.
https://academic.oup.com/jncics/article/8/3/pkae017/7661034?login=true 

Boland PM, Mukherjee S, Imanirad I, Vijayvergia N, Cohen SD, Gupta M, Iyer RV, Bakin A, Wang J, Chatley S, Cahill B, Vadehra D, Attwood K, Hochster HS, Fountzilas C. TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. Br J Cancer. 2024 Sep 7. doi: 10.1038/s41416-024-02845-x. Online ahead of print.  PMID: 39244627.
https://www.nature.com/articles/s41416-024-02845-x 

Tella SH, Foster N, Qian S, Nguyen T, Borad MJ, McWilliams RR, Alberts SR, Ma WW, Chakrabarti S, Fruth B, Wessling J, Hartgers M, Washburn L, Fernandez-Zapico ME, Hogenson TL, Pitot H, Jin Z, Mahipal A. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. Oncologist. 2023 Jun 20:oyad144. doi: 10.1093/oncolo/oyad144. Epub ahead of print. PMID: 37339254.
https://pubmed.ncbi.nlm.nih.gov/37339254/

Gynecologic Cancer

Chelariu-Raicu A, Vu TC, Umamaheswaran S, Stur E, Hanjra P, Han Y, Hu M, Lin J, Lawson BC, Liu J, Sood AK, Wen Y. IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer.  Cancer Research Communications (2025) 5 (3): 512–526.
https://doi.org/10.1158/2767-9764.CRC-24-0215

Cristea MC, Stewart D, Synold T, Ruel N, Mortimer J, Wang E, Jung A, Wilczynski S, Konecyn GE, Eng M, Kilpattrick L, Han E, Dellinger H, Hakim A, Lee S, Morgan RJ, Wakabayashi T, Frankel PH.  A Phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer. Gynecologic Oncology Vol 182, p124-131, March 2024. https://doi.org/10.1016/j.ygyno.2023.12.017  

Cowan M, Swetzig WM, Adomo-Cruz V, Pineda MJ, Neubauer NL, Berry E, Lurain JR, Shahabi S, Taiym D, Nelson V, O'Shea KL, Kocherginsky M, Matei D. Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. Gynecol Oncol. 2021 Oct;163(1):57-63. doi: 10.1016/j.ygyno.2021.08.005. Epub 2021 Aug 18. https://pubmed.ncbi.nlm.nih.gov/34419285/

Kovisto CS, Parrish Santosh M, Bonala B, Ngoi S, Torres A, Gallagher J, Sanchez-Hodge R, Zeinner V, Nahhas GJ, Liu B, Cohn DE, Backs FJ, Goodfellow J, Chamberlin HM, Leone G.  Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.  Neoplasia Volume 22, Issue 10, October 2020, Pages 484-496.  https://www.sciencedirect.com/science/article/pii/S1476558620301342

Head and Neck Cancer

Mudianto T, Campbell K, Webb J, Zolkind P, Skidmore Z, Riley R, Barnell E, Ozgenc I, Giri T, Dunn G, Adkins D, Griffith M, Egloff A, Griffith O, Uppaluri R.  Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2021 Apr 15;27(8):2326-2339.  doi: 10.1158/1078-0432.CCR-19-4179.  Epub 2021 Feb 5.
https://pubmed.ncbi.nlm.nih.gov/33547198/

Swiecicki PL, Bellile E, Brummell C, Brenner JC, Worden FP.  Efficacy of axitinib in metastatic head and neck cancer using novel radiographic response criteria.  Cancer 20 October 2020.
https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33226

Hematologic Cancer

Torka P,  Akhtar OS,  Reddy NM, Baysal BE,  Kader A, Groman A,  Nichols J, Mavis C,  Tario JD,  Block AM, Sait SN, Ghione P,  Sundaram S, PrzespolewskiER, Mohr A,  Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley RN, Wallace PK, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ. Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. Cancer 2022 Apr; 128(8):1595-1604. 
https://doi.org/10.1002/cncr.34106

Mehta-Shah N, Lunning MA, Moskowitz AJ, Boruchov AM, Ruan J, Lynch P, Hamlin PA, Leonard J, Matasar MJ, Myskowski PL, Marzouk E, Nair S, Sholklapper T, Minnal V, Palomba ML, Vredenburgh J, Kumar A, Noy A, Straus DJ, Zelenetz AD, Schoder H, Rademaker J, Schaffer W, Galasso N, Ganesan N, Horwitz SM. Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts. Am J Hematol. 2021 Oct 1;96(10):1211-1222. doi: 10.1002/ajh.26288. Epub 2021 Jul 29. PMID: 34251048
https://pubmed.ncbi.nlm.nih.gov/34251048/

Chow VA, Martin PS, Smith SD, Till BG, Graf SA, Edlefsen KL, Hannan LM, Mostaghel EA, Gopal AK.  Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.  Br Journal of Haematol, First published: 22 June 2020, doi.org/10.1111/bjh.16902.
https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16902?af=R

Ma S, Rosen ST, Winqvist M, Frankfurt O, Winter JN, Gordon L, Helenowski I, Zhang H, Kreutzer J, Sönnert-Husa S,  Österborg A, Lundin J. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study. Leukemia Research Volume 122, 2022, 106945, ISSN 0145-2126, https://doi.org/10.1016/j.leukres.2022.106945 

Kambhampati S,  Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clinical Lymphoma Myeloma and Leukemia 2020. doi:10.1016/j.clml.2020.12.020
https://doi.org/10.1016/j.clml.2020.12.020

Lampson BL, Kim HT, Davids MS, Abramson JS,  Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ,  Kipps TJ, Fein J,  Fernandes SM, Hanna JR, Fisher DC, and  Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Advances  2019 3:1167-1174.
https://doi.org/10.1182/bloodadvances.2018030221

Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G,  Wierda WG, Keating MJ, and Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies.  J Geriatr Oncol. 2020 Jan;11(1):19-23. doi: 10.1016/j.jgo.2019.04.002. Epub 2019 Apr 18.
https://www.ncbi.nlm.nih.gov/pubmed/31005650

Hepatocellular Carcinoma

Kelley RK, Joseph NM, Nimeiri HS, Hwang J, Kulik LM, Ngo Z, Behr SC, Onodera C, Zhanag K, Bocobo AG, Benson AB, Venook AP, Gordon JD. Temsirolimus combined with sorafenib in hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer 2021. doi: 10.1159/000518297 https://www.karger.com/Article/FullText/518297

El Dika I, Capanu M, Chou JF, Harding J, Ly M, Hrabovsky A, Do R, Shia J, Millang B, Ma J, O'Reilly E, Abou-Alfa G. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Med. 2020;00:1–7. https://doi. org/10.1002/cam4.3389
https://doi.org/10.1002/cam4.3389

Harding, JJ, Kelley RK, Tan B, Capanu M, Lobst, Do R, Shia J, Chou JF, Boussayoud C, Ferrere C, Muenkel KE, Yarmohammadi H, El Dika I, Khalil D, Ruiz , Rodriguez MR, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. Phase 1b study of enzalutamide with or without sorafenib in patients with advanced hepatocellular carcinoma.  The Oncologist on line 16 June 2020
https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2020-0521

Fountzilas C, Gupta M, Lee S, Krishnamurthi  S, Estfan B, Wang K, Attwood K, Wilton J, Bies R, Bshara W, Iyer R. A Multicentre Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma.  Br J Cancer. 2020 Mar;122(7):963-970. doi: 10.1038/s41416-020-0737-6. Epub 2020 Feb 10.
https://pubmed.ncbi.nlm.nih.gov/32037403/

Lung Cancer

Myall NJ, Whisenant JG, Neal JW, Iams WT, Reckamp KL, York S, Berry LD, Shyr Y, Horn L, Wakelee HA, Padda SK. Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors. JTO Clinical and Research Reports Vol. 6 No. 2: 100757. Online Nov 4, 2024. https://www.jtocrr.org/article/S2666-3643(24)00127-9/pdf

Auberle C, Gao F, Sloan M, Morgensztern D, Winkler L, Ward JP, Devarakonda S, Rearden TP, Govindan R, Waqar SN. A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer. J Thorac Dis 2024. doi: 10.21037/jtd-23
https://jtd.amegroups.org/article/view/87108/pdf    

Bodor J,Patel J, Wakelee H, Levy B, Borghaei H, Pellini B, Costello M, Dowell J, Finley G, Huang C, Neal J, Nieva J, Puri S, Socinski M, Thomas C, Ross E, Litwin S, Clapper M, Treat J. Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked. Clinical Lung Cancer Published:May 10, 2023 DOI:https://doi.org/10.1016/j.cllc.2023.05.003. 
https://www.clinical-lung-cancer.com/article/S1525-7304(23)00097-9/abstract

Dy G, Prasad D, Kumar P, Attwood K, Adjei A.  A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.  J Thorac Oncol. 2021 Mar;16(3):e19-e20.  doi: 10.1016/j.jtho.2020.11.019.
https://pubmed.ncbi.nlm.nih.gov/33641724/

Neal JW, Costa D, Muzikansky A, Shrager J, Lanuti M, Huang J, Ramachandran K, Rangaschari D, Huberman M, Piotrowski Z, Kris M, Azzoli C, Sequist L, Chaft J .  Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients with Surgically Resected Stage I-III EGR-Mutant Non-Small-Cell Lung Cancer.  JCO Precision Oncology No.5(2021) 325-332.  Published online 2/2/21. DOI: 10.1200/PO.20.00301
https://ascopubs.org/doi/full/10.1200/PO.20.00301?journalCode=po

Melanoma

Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MA. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. The Oncologist. 2021 Apr 16. doi: 10.1002/onco.13795. https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13795

Neuroendocrine Tumors

Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Suffren S, Hicks K, Wilton J, Bies, R, Casucci D, Reidy-Lagunes D, Shah M.   Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer. 2020 Aug 15;126(16):3689-2697. Epub 2020 Jun 11. doi:10.1002/cncr.32994
https://pubmed.ncbi.nlm.nih.gov/32525561/

Prostate Cancer

Shee K, de la Calle C, Chang A, Wong, A, Feng F, Gottschalk A, Carroll P, Nguyen H. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial, Shee, Kevin et al, Advances in Radiation Oncology, Volume 7, Issue 5, 100941, March 11, 2022. 
https://www.advancesradonc.org/article/S2452-1094(22)00048-3/fulltext

Quality Improvement

Stearns, V., Chen, R., Blackford, A.L. et al. The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer. Breast Cancer Res Treat (2025). https://link.springer.com/article/10.1007/s10549-024-07591-5

Kumar A, Owen JR, Sloat NT, Maynard E, Hill VM, Hubbard CB, McKinney MS, Sutton LM, McCall SJ, Datto MB, Moyer AN, Caughey BA, Strickler JH, Ramaker RC. Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States. Curr Oncol. 2024 Nov 16;31(11):7244-7257. doi: 10.3390/curroncol31110534. PMID: 39590164; PMCID: PMC11593073. https://pubmed.ncbi.nlm.nih.gov/39590164/

Marmarelis ME, Scholes DG, McWilliams TL, Hwang WT, Kosteva J, Costello MR, Sun L, Singh AP, Lau-Min KS, Doucette A, Gabriel PE, Martella AO, Roy MA, Thompson JC, Cohen RB, Dougherty DW, Shulman LN, Langer CJ, Bekelman JE, Carpenter EL, Aggarwal C. Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical Trial. JCO Oncol Pract. 2024 Jul 3:OP2400070. doi: 10.1200/OP.24.00070. Epub ahead of print. PMID: 38959441. https://ascopubs.org/doi/10.1200/OP.24.00070 

Wright AA, Poort H, Tavormina A, Schmiege SJ, Matulonis UA, Campos SM, et al. Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue. Gynecologic Oncology. 2023 Oct 1;177:165–72. 
https://doi.org/10.1016/j.ygyno.2023.08.020 

Aggarwal C, Marmarelis ME, Hwang W-T, Scholes DG, McWilliams TL, Singh AP, Sun L, Kosteva J, Costello MR, Cohen RB, Langer CL, Doucette A, Gabriel PN, Shulman LN, Rendle KA, Thompson JC, Bekelman JE, Carpenter EL. Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. DOI: 10.1200/PO.23.00191 JCO Precision Oncology no. 7 (2023) e2300191. Published online July 27, 2023.
https://ascopubs.org/doi/pdf/10.1200/PO.23.00191?role=tab

Fleege N, Pierce-Gjeldum D, Swartz LK, Verbal K, Merajver S, Friese CR, Kiyota A, Heth J, Leung D, Smith SR, Gabel N, Kim MM, Morikawa A. IMPACT the Brain: A Team-Based Approach to Management of Metastatic Breast Cancer with Central Nervous System Metastases. JCO Oncol Pract. 2023 Jan;19(1):e67-e77. doi: 10.1200/OP.22.00291. Epub 2022 Oct 12.
https://pubmed.ncbi.nlm.nih.gov/36223556/ 

Wickline M, Wolpin S, Cho S, Tomashek H, Louca T, Frisk T, Templin J, Loechl A, Goff B, Berry D. Usability and acceptability of the electronic self-assessment and care (eSAC) program in advanced ovarian cancer: A mixed methods study. Gynecol Oncol. 2022 Sep 20:S0090-8258(22)01825-X. doi: 10.1016/j.ygyno.2022.09.010. Epub ahead of print. PMID: 36150917.
https://pubmed.ncbi.nlm.nih.gov/36150917/

Waldman LP, Centracchio JA, Jacobs JM, Petrillo LA, El-Jawahri AR, Temel JS and Greer JA (2023) Study protocol for a randomized trial of a supportive care mobile application to improve symptoms, coping, and quality of life in patients with advanced non-small cell lung cancer. Front. Psychol. 14:1184482. doi: 10.3389/fpsyg.2023.1184482.
https://www.frontiersin.org/articles/10.3389/fpsyg.2023.1184482/full

Rectal Cancer

Wu C, Williams TM, Robb R, Webb A, Wei L, Chen W, Mikhail S, Ciombor KK, Cardin DB, Timmers C, Krishna SG, Arnold M, Harzman A, Abdel-Misih S, Roychowdhury S, Bekaii-Saab T, Wuthrick E. Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.  Clin Cancer Res. 2020 26(13):3117-3125. doi: 10.1158/1078-0432.CCR-19-4193.
https://aacrjournals.org/clincancerres/article/26/13/3117/82637/Phase-I-Trial-of-Trametinib-with-Neoadjuvant

Thyroid Cancer

Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C, Shah MH. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid. 2022 Jul 5. doi: 10.1089/thy.2022.0115. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35658604/ 

NCCN ORP Abstracts

Brain Cancer

Ly I, Richardson L, Liu M, Muzikansky A, Lou K, Reardon DA, Arrillaga-Romany I, Forst DA, Jordan JT, Lee EQ, Dietrich J, Nayak L, Wen PY, Chukwueke UN, Giobbie-Hurder A, Choi BD, Batchelor T, Kalpathy-Cramer J, Curry WT, Gerstner ER. Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma. J Clin Oncol 40, 2022 (suppl 16; abstr 2030).
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.2030

Ly KI, Cardona J, Lou K, Beers AL, Chang K, Brown JM, Reardon DA,  Arrillaga-Romany IC, Forst DA,Jordan JT, Lee EQ, Dietrich J, Nayak L, Wen PY, Chukwueke U, Batchelor TT, Curry WT, Kalpathy-Cramer J, Gerstner ER. MRI changes in patients with newly diagnosed glioblastoma treated as part of a Phase II trial with bavituximab, radiation, and temozolomide.  MRI changes in patients with newly diagnosed glioblastoma treated as part of a Phase II trial with bavituximab, radiation, and temozolomide.  J Clin Oncol 38: 2020 (suppl; abstr 2546). https://meetinglibrary.asco.org/record/189390/abstract 

Breast Cancer

Gil M, Yu T, Alderson M, Takabe K, D’Assoro A, Li S, Opyrchal M. (2025). PCO25-209: Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Inhibition of ER Positive Breast Cancers in Acquired Resistance PDX Model. Journal of the National Comprehensive Cancer Network, 23(3.5), PCO25-209. https://doi.org/10.6004/jnccn.2024.7309

Gastrointestinal Cancer

Kim D, Ponto L, Pereira A, Kim R, Kracht C, Lauwers G, Pimiento J, Biachi de Castria T, Strosberg J, Haider M, Imanirad I, Avriett T, Costello J, Hoffe S, Chen D, Mukherjee S, Mehta R.  A phase II study of neratinib (Nera) in combination with chemotherapy/trastuzumab/pembrolizumab (C/T/P) in HER2 overexpressing gastroesophageal cancers (GECs). J Clin Oncol 43, 2025 (suppl 4; abstr TPS514).
https://meetings.asco.org/abstracts-presentations/241415

Nakrani, R., Singh, T., Handorf, E., Alpaugh, K. R., & Vijayvergia, N. TIP24-198: A Multi-Center Phase I Trial of Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Refractory Gastric Cancer Patients. J Natl Compre Cancer Netw, Apr 5, 2024 22(2.5). 
https://doi.org/10.6004/jnccn.2023.7221

Mukherjee S, Alarcon S, Fountzilas C, Chatley S, Iyer R, Vadehra D, Kukar M, Attwood K, George A, Brown A, Liao C, Hatoum H, George S. Trifluridine/tipiracil (FTD/TPI) and oxaliplatin as induction chemotherapy (IC) in resectable esophageal and gastroesophageal junction adenocarcinoma (EGAC): Preliminary results from a phase II study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT146.
https://aacrjournals.org/cancerres/article/83/8_Supplement/CT146/725191/Abstract-CT146-Trifluridine-tipiracil-FTD-TPI-and

Boland PM, Mukherjee S, Imanirad I, Vijayvergia N, Cohen SD, Gupta M, Iyer RV, Chatley S, Cahill B, Vadehra D, Attwood K, Hochster HS, Fountzilas C.  Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO). J Clin Oncol 41, 2023 (suppl 16; abstr 3590).
https://meetings.asco.org/abstracts-presentations/220278  

Gupta, M, Fountzilas C, Vijayvergia N, Attwood K, Hochster HS, Mukherjee S, Iyer R, Boland PM. A Phase II Study of Trifluridine/tipiracil, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO). Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS275

Xie H, Borad MJ,  Ahn DH, Bekaii-Saab TS, Tran NH, Jin Z, Pitot HC, Huebner LJ, Shi Q, Wessling J, Durgin LM,  Liu MC, Hogenson TL, Phillips WJ, Fernandez-Zapico M, Alberts SR, Mahipal A.  Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer. Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS594

Mukherjee S,  Assi H, Fountzilas C, Attwood K, Boland P, Iyer R, Catenacci DV,  Hatoum H.  Phase II Study of Trifluridine/Tipiracil (FTD/TPI) and Oxaliplatin as Induction Chemotherapy (IC) in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma (EGAC)Journal of Clinical Oncology 38, no. 4_suppl.  Published on line February 04, 2020. 
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.4_suppl.TPS464

Gynecologic Cancer

Berry DL, Wolpin S, Pike K, Cho S, Goff BA.  Patient-generated outcomes, questions and concerns: Quantitative and open text methods and relationships with palliative care referrals in advanced ovarian cancer. JCO Oncol Pract 19, 259-259(2023).  DOI:10.1200/OP.2023.19.11_suppl.259.  https://ascopubs.org/doi/10.1200/OP.2023.19.11_suppl.259 

Cristea MC, Ruel NH, Frankel PH, Synold TW, Stewart DB, Wang EW, Jung A, Wilczynski S, Tran M, Konecyn GE, Eng M, Kilpatrick L, Chen Y, Glaser S, Dellinger TH, Hakim A, Lee S, Morgan R, Han ES. A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort. J Clin Oncol 39, 2021 (suppl 15; abstr 5542) https://meetings.asco.org/abstracts-presentations/197431/abstract

Westin SN, Fellman B, Yuan Y, Soliman PT, Fleming ND, Cobb L, Shafer A, Taylor J, Jazaeri A, Frumovitz M, Ramirez PT, Meyer LA, Alvarado T, Hull S, Lu KH, Mills GB, Coleman RL. ENPAC: Phase II trial with a limited safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced and recurrent endometrioid endometrial adenocarcinoma. SUNDAY_2021- SGO Virtual-Annual-Meeting-on-Womens-Cancer.

Cristea MC, Frankel P, Synold T, Stewart DB, Wang E, Jung A, Wilczynski S, Tran M, Konecny GE, Eng M, Kilpatrick L, Chen Y, Glaser S, Han E, Dellinger T, Hakim A, Lee S, Morgan RJ, Rodriguez L, Wakabayashi M.  A Phase I Study of Mirvetuximab Soravtansine (MIRV) and Gemcitabine (G) in Patients (Pts) with selected FRα -positive solid tumors: Results in the Endometrial Cancer (EC) Cohort.  Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276
https://www.annalsofoncology.org/article/S0923-7534(20)40998-6/fulltext

Chelariu-Raicu A, Stur E, Ivan C, Coleman RL, Sood AK, Wen Y. Biological effects of a FRα-targeting antibody-drug conjugate, IMGN853 (mirvetuximab soravtansine) in high-grade serous ovarian cancer. In: Proceedings of the 111th Annual Meeting of the American Association for Cancer Research; 2020 June 22-24. Philadelphia (PA): AACR; 2020. Abstract 1237/20
https://www.abstractsonline.com/pp8/#!/9045/presentation/3480

Lung Cancer 

Rose J, Gosula V, Cho S, Sadri N, Yoest J, Donner A, Bruno DS.  Cost Effectiveness of a System-Level Precision Medicine Intervention for Stage IV Non-Small Cell Lung Cancer Patients. World Lung 2024. Online Only. https://cattendee.abstractsonline.com/meeting/20598/Session/304

Bodor JB, Patel JD, Ross EA, Litwin S, Clapper M, Levy BP, Wakelee HA, Borghaei H, Treat J: Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, +/- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked. J Clin Oncol 38: 2020
https://meetings.asco.org/abstracts-presentations/191802/abstract 

Waqar SN, Rawat U, Morgensztern D, Shah S, Ward JP, Devarakonda SH, Rearden TP, Gao F, Govindan R. A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer (NSCLC) (NCT02299141). J Clin Oncol 38: 2020 (suppl; abstr e21694). 
https://meetings.asco.org/abstracts-presentations/185721/abstract

Prostate Cancer

Roy AM, Gopalakrishnan D, Jatwani K, Green K, Farmer B, Jaiswal N, Attwood K, Levine EG, Beltran H, Goodrich D, Chatta GS.  A phase Ib trial of enzalutamide with oral decitabine/cedazuridine in metastatic castration-resistant prostate cancer (CRPC).   J Clin Oncol 42, 2024 (suppl 4; abstr TPS252). https://meetings.asco.org/abstracts-presentations/230435

de la Calle CM, Chang, A, Rashid G, Wong AC, Choi A, Feng FY, Gottschalk AR, Menzel PL , Carroll P, Nguyen HG.  Phase II trial of definitive radiotherapy with leuprolide and enzalutamide in high-risk prostate cancer.  J Clin Oncol 38, 2020 (suppl 6; abstr 323).  
https://meetings.asco.org/abstracts-presentations/183514/abstract

Quality Improvement Studies

Shahamatdar S, Clifton K, Wu J, Putur A, Kuter I, Bardia A, Juric D, Spring L, Harris K, Moy B, Shin J, Vidula N, Ma C, Wander SA. San Antonio Breast Cancer Symposium 2024. Abstract Number: SESS-1511 (P4-10-12).  Online Only
https://sabcs.org/Call-for-Abstracts-2024

Marmarelis ME, Scholes DG, McWilliams TL, Hwang W-T, Kosteva JA, Costello MR, Sun LL, Singh AP, Lau-Min KS, Doucette A, Gabriel PE, Martella AO, Roy M, Thompson JC, Cohen RB, Dougherty DW, Shulman LN, Langer CJ, Bekelman JE, Carpenter EL, Aggarwal C. Prospective Trial of an EMR-based Nudge to Increase Molecular Genotyping in Newly Diagnosed Metastatic Non-squamous NSCLC. Abstract MA14.04, 2023 World Conference on Lung Cancer, September 11, 2023. https://cattendee.abstractsonline.com/meeting/10925/Session/113

Wright AA, Poort H, Tavormina A, Schmiege S, Matulonis UA, Campos SM, Liu JF, Slivjak E, Gilmour A, Salinger J, Haggerty AF, Arch JA. Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue. Journal of Clinical Oncology 2023 41:16_suppl, e24122-e24122. 
https://meetings.asco.org/abstracts-presentations/225422  

Aggarwal C, Marmarelis ME, Hwang W-T, Scholes DG, McWilliams T, Singh AP, Sun L, Kosteva JA, Costello MR, Cohen RB, Langer CL, Gabriel PE, Shulman LN, Thompson JC, Carpenter EL. Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer. Journal of Clinical Oncology 2022 40:16_suppl, 9022-9022.
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.9022

Bruno DS, Donner AL, Kopp SR, Yoest J, Mneimneh W, Margevicius S, Shanahan J, Fu P, Hsu ML, Afshin Dowlati A, Sadri N. Implementation of a precision medicine thoracic (PREDICT) service using reflex testing in a large academic-community practice network. Journal of Clinical Oncology 2022 40:16_suppl, 6572-6572.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.6572